-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![ASCO GI 22 FIT featured](https://volition.com/wp-content/uploads/2024/02/ASCO-GI-22-FIT-featured-e1708341102806.jpg)
Circulating nucleosomes levels improve FIT performance for detecting high-risk colorectal neoplasms in a symptomatic population
- Share
- Tweet
- Share on Facebook
- Share
![ASCO GI 22 FIT thumbnail](https://volition.com/wp-content/uploads/2024/02/ASCO-GI-22-FIT-thumbnail.jpg)
![ASCO GI 22 FIT thumbnail](https://volition.com/wp-content/uploads/2024/02/ASCO-GI-22-FIT-thumbnail.jpg)
Poster title: “Circulating nucleosomes levels improve FIT performance for detecting high-risk colorectal neoplasms in a symptomatic population.”
Presented at ASCO 2022
Chang et al
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields